KRAS and colorectal carcinoma: Notably, Assenat and colleagues [12] previously designed a single-arm study to investigate the efficacy of cetuximab plus a modified FOLFOXIRI regimen in advanced CRC and found that the overall ORR was 80.9% for KRAS wild-type patients, while PFS and OS were 9.5 and 24.7 months, respectively.